Identification of Phosphatidylinositol 3-kinase δ (PI3Kδ) Inhibitor: Pharmacophore-based Virtual Screening and Molecular Dynamics Simulation

Muhammad Arba; Malindo Sufriadin; Daryono Hadi Tjahjono

doi:10.22146/ijc.47327

Identification of Phosphatidylinositol 3-kinase δ (PI3Kδ) Inhibitor: Pharmacophore-based Virtual Screening and Molecular Dynamics Simulation

https://doi.org/10.22146/ijc.47327

Muhammad Arba^(1*), Malindo Sufriadin⁽²⁾, Daryono Hadi Tjahjono⁽³⁾

(1) Faculty of Pharmacy, Halu Oleo University, Jl. Kampus Hijau Bumi Tridharma, Anduonou, Kendari 93132, Southeast Sulawesi, Indonesia
(2) Faculty of Pharmacy, Halu Oleo University, Jl. Kampus Hijau Bumi Tridharma, Anduonou, Kendari 93132, Southeast Sulawesi, Indonesia
(3) School of Pharmacy, Institut Teknologi Bandung, Jl. Ganesha No. 10, Bandung 40132, West Java, Indonesia
(*) Corresponding Author

Abstract

Phosphatidylinositol 3-kinase δ (PI3Kδ) is a validated drug target for the treatment of cancer. The present study aims to search for new inhibitors of PI3Kδ by employing pharmacophore modelling using LigandScout Advanced 4.3 software. The three hydrogen bond acceptors and two hydrophobic features were proposed as a pharmacophore model using LASW1976 structure. The model was then validated using the Area Under Curve (AUC) of Receiver Operating Characteristic (ROC) and GH score. It was used to screen new molecules in the ZINC database, which resulted in 599 hits. All 599 hits were then docked into PI3Kδ protein, and five best hits were submitted to 50 ns molecular dynamics simulations. Each hit complexed with PI3Kδ underwent minor conformational changes as indicated by the values of Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF). Furthermore, prediction of the binding free energy using Molecular Mechanics-Poisson Boltzmann Surface Area (MM-PBSA) method showed that five hits, i.e., Lig25/ZINC253496376, Lig682/ZINC98047241, Lig449/ZINC85878047, Lig554/ZINC253389510, and Lig199/ZINC12638303, had lower binding energy compared to LASW1976. This result indicated their potentials as new inhibitors of PI3Kδ.

Keywords

PI3K; molecular docking; pharmacophore modeling; molecular dynamics simulation

Full Text:

Full Text PDF Full Text PDF - Suppl. Data

References

[1] Ameriks, M.K., and Venable, J.D., 2009, Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma, Curr. Top. Med. Chem., 9 (8), 738–753.

[2] Hoegenauer, K., Soldermann, N., Hebach, C., Hollingworth, G.J., Lewis, I., von Matt, A., Smith, A.B., Wolf, R.M., Wilcken, R., Haasen, D., Burkhart, C., and Zécri, F., 2016, Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties, Bioorg. Med. Chem. Lett., 26 (23), 5657–5662.

[3] Vanhaesebroeck, B., Stephens, L., and Hawkins, P., 2012, PI3K signalling: The path to discovery and understanding, Nat. Rev. Mol. Cell Biol., 13 (3), 195–203.

[4] Ma, C.C., Zhang, C.M., Tang, L.Q., and Liu, Z.P., 2018, Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors, Eur. J. Med. Chem., 151, 9–17.

[5] Hoegenauer, K., Soldermann, N., Stauffer, F., Furet, P., Graveleau, N., Smith, A.B., Hebach, C., Hollingworth, G.J., Lewis, I., Gutmann, S., Rummel, G., Knapp, M., Wolf, R.M., Blanz, J., Feifel, R., Burkhart, C., and Zécri, F., 2016, Discovery and pharmacological characterization of novel quinazoline-based PI3K delta-selective inhibitors, ACS Med. Chem. Lett., 7 (8), 762–767.

[6] Rowan, W.C., Smith, J.L., Affleck, K., and Amour, A., 2012, Targeting phosphoinositide 3-kinase δ for allergic asthma, Biochem. Soc. Trans., 40 (1), 240–245.

[7] Nair, K.S., and Cheson, B., 2016, The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia, Ther. Adv. Hematol., 7 (2), 69–84.

[8] Göckeritz, E., Kerwien, S., Baumann, M., Wigger, M., Vondey, V., Neumann, L., Landwehr, T., Wendtner, C.M., Klein, C., Liu, N., Hallek, M., Frenzel, L.P., and Krause, G., 2015, Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells, Int. J. Cancer, 137 (9), 2234–2242.

[9] Bashash, D., Safaroghli-Azar, A., Dadashi, M., Safa, M., Momeny, M., and Ghaffari, S.H., 2017, Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib, Int. J. Biochem. Cell Biol., 85, 149–158.

[10] Flinn, I.W., Patel, M., Oki, Y., Horwitz, S., Foss, F.F., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kharidia, J., Kelly, P., Kelly, V.M., and Kahl, B., 2018, Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study, Am. J. Hematol., 93 (11), 1311–1317.

[11] Erra, M., Taltavull, J., Bernal, F.J., Caturla, J.F., Carrascal, M., Pagès, L., Mir, M., Espinosa, S., Gràcia, J., Domínguez, M., Sabaté, M., Paris, S., Maldonado, M., Hernández, B., Bravo, M., Calama, E., Miralpeix, M., Lehner, M.D., and Calbet, M., 2018, Discovery of a novel inhaled PI3Kδ inhibitor for the treatment of respiratory diseases, J. Med. Chem., 61 (21), 9551–9567.

[12] Arba, M., Nur-Hidayat, A., Surantaadmaja, S.I., and Tjahjono, D.H., 2018, Pharmacophore-based virtual screening for identifying β5 subunit inhibitor of 20S proteasome, Comput. Biol. Chem., 77, 64–71.

[13] Arba, M., Yamin, Ihsan, S., and Tjahjono, D.H., 2018, Computational approach toward targeting the interaction of porphyrin derivatives with Bcl-2, J. Appl. Pharm. Sci., 8 (12), 60–66.

[14] Wolber, G., and Langer, T., 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45 (1), 160–169.

[15] Gilson, M.K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L., and Chong, J., 2016, BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res., 44 (D1), D1045–D1053.

[16] Mysinger, M.M., Carchia, M., Irwin, J.J., and Shoichet, B.K., 2012, Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking, J. Med. Chem., 55 (14), 6582–6594.

[17] Sunseri, J., and Koes, D.R., 2016, Pharmit: interactive exploration of chemical space, Nucleic Acids Res., 44 (W1), W442–W448.

[18] Irwin, J.J., Sterling, T., Mysinger, M.M., Bolstad, E.S., and Coleman, R.G., 2012, ZINC: A free tool to discover chemistry for biology, J. Chem. Inf. Model., 52 (7), 1757–1768.

[19] Li, H., Leung, K.S., and Wong, M.H., 2012, Idock: A multithreaded virtual screening tool for flexible ligand docking, 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), San Diego, California, USA, 9–12 May 2012, 77–84.

[20] Case, D.A., Cheatham, T.E., Darden, T., Gohlke, H., Luo, R., Merz, K.M., Onufriev, A., Simmerling, C., Wang, B., and Woods, R.J., 2005, The Amber biomolecular simulation programs, J. Comput. Chem., 26 (16), 1668–1688.

[21] Salomon-Ferrer, R., Götz, A.W., Poole, D., Le Grand, S., and Walker, R.C., 2013, Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald, J. Chem. Theory Comput., 9 (9), 3878–3888.

[22] Maier, J.A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K.E., and Simmerling, C., 2015, ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB, J. Chem. Theory Comput., 11 (8), 3696–3713.

[23] Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A., and Case, D.A., 2004, Development and testing of a general amber force field, J. Comput. Chem., 25 (9), 1157–1174.

[24] Jakalian, A., Jack, D.B., and Bayly, C.I., 2002, Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation, J. Comput. Chem., 23 (16), 1623–1641.

[25] Ryckaert, J.P., Ciccotti, G., and Berendsen, H.J.C., 1977, Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes, J. Comput. Phys., 23 (3), 327–341.

[26] Darden, T., York, D., and Pedersen, L., 1993, Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems, J. Chem. Phys., 98 (12), 10089.

[27] Roe, D.R., and Cheatham III, T.E., 2013, PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data, J Chem Theory Com, 9 (7), 3084–3095.

[28] Humphrey, W., Dalke, A., and Schulten, K., 1996, VMD: Visual molecular dynamics, J. Mol. Graphics, 14 (1), 33–38.

[29] Kollman, P.A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D.A., and Cheatham, T.E., 2000, Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models, Acc. Chem. Res., 33 (12), 889–897.

[30] Arba, M., Kartasasmita, R.E., and Tjahjono, D.H., 2016, Molecular docking and dynamics simulations on the interaction of cationic porphyrin-anthraquinone hybrids with DNA G-quadruplexes, J. Biomol. Struct. Dyn., 34 (2), 427–438.

[31] Miller, B.R., McGee, T.D., Swails, J.M., Homeyer, N., Gohlke, H., and Roitberg, A.E., 2012, MMPBSA.py: An efficient program for end-state free energy calculations, J. Chem. Theory Comput., 8 (9), 3314–3321.

[32] Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., and Olson, A.J., 1998, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem., 19 (14), 1639–1662.

DOI: https://doi.org/10.22146/ijc.47327